Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06701890

Observational Study of Travellers Pathologies

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.

The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical Center of Institut Pasteur

Paris, 75015, France

Location status: Recruiting

Location contact

Fabien TAIEB, MD

CONTACT

[email protected]

About this study

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.

The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.

To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.

  • EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected.
  • EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

  • Inclusion Criteria :
  • For all participants in the EOP study :
  • Major subject (age ≥ 18)
  • Owns a smartphone compatible with electronic data collection
  • Preparing to travel outside mainland France
  • Affiliated with or covered by Social Security or private insurance
  • Willing to participate in the EOP study
  • For the EOP-Arbo Sub-study :
  • Subject who has consented to participate in the EOP_Arbo study.
  • For the EOP-AMR Sub-study :
  • Subject who has consented to participate in the EOP_AMR study.
  • Exclusion Criteria:
  • For all participants in the EOP study :
  • Travel duration ≤ 3 days
  • Travel duration > 12 months
  • Person traveling as part of an expatriation without planned movement outside the settlement in the destination country
  • Person under legal protection or unable to express consent for participation
  • For the EOP-Arbo Sub-study :
  • Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study.
  • For the EOP-AMR Sub-study :
  • No specific exclusion criteria.

Treatment and study plan

Blood Sample Collection

Other

16 mL at inclusion 16 mL at 1 month after return from travel

Fecal Sample Collection

Other

1 sample at inclusion

1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel

Primary outcomes

  1. Determine the incidence of pathologies occurring during a travel outside the metropolitan territory.

    Time frame: 10 years

    Number of subjects who developed a pathology during the travel among participants

Secondary outcomes

  1. For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel.

    Time frame: 10 years

    Number of arboviral diseases (dengue, chikungunya, Zika) during the travel among participants

  2. For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel.

    Time frame: 10 years

    Proportion of subjects with multi-resistant bacteria acquired during the travel

Study contacts

Contact information is provided by the study sponsor or research team.

Fabien TAIEB, MD

CONTACT

[email protected]

0140613456 ext. +33

Julia ABAD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Institut Pasteur

Industry

Registry information

Acronym: EOP

Important dates

Study start
2024
Primary completion
2034
Study completion
2036
First posted
Nov 22, 2024
Registry last updated
May 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.